Company IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
Business Summary
Number of employees: 160
Managers
Managers | Title | Age | Since |
---|---|---|---|
John D. Hoekman
FOU | Founder | 43 | 07-12-31 |
Sheena Aurora
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Youmans
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
Sarah Wille
HRO | Human Resources Officer | - | 18-12-31 |
Lynn Gold
LAW | General Counsel | 67 | 18-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Nelson
BRD | Director/Board Member | 60 | 17-01-31 |
Ali Satvat
BRD | Director/Board Member | 46 | 18-12-06 |
Diane Wilfong
BRD | Director/Board Member | 62 | 19-09-16 |
David Allison
BRD | Director/Board Member | 42 | 19-05-31 |
John D. Hoekman
FOU | Founder | 43 | 07-12-31 |
Darren Cline
BRD | Director/Board Member | 59 | 23-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,900,031 | 23,880,031 ( 99.92 %) | 0 | 99.92 % |
Company contact information
Impel Pharmaceuticals, Inc.
201 Elliott Avenue West Suite 260
98119, Seattle
+206 568 1466
http://impelpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |